Close Menu

The Wall Street Journal says to expect "an uptick in acquisitions of small and midsize drug companies" but that large pharma companies are "not going on reckless shopping sprees." Bristol-Myers' Karen LaRochelle said that many in Big Pharma do have a bit of cash "and there's a lot of pressure for us to build our pipelines." Merck's Richard Kender adds that, due to the current market, deals that in the past may have been deemed "marginal" are now more likely.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Two researchers are calling for education for scientists on defending facts.

Researchers were among those who marched in London this weekend to call for another vote on Brexit.

Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant. 

In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.